Understanding FVIII/VWF complex - report from a symposium of XXIX WFH meeting 2010

Haemophilia

Volumn 18, Issue 3, 2012, Pages 469-475

  Gringeri, A ^a   Ofosu, F A ^b   Grancha, S ^c   Oldenburg, J ^d   Ewing, N P ^e   Federici, A B ^f  

^a UNIVERSITY OF MILAN   (Italy)

^b MCMASTER UNIVERSITY   (Canada)

^c Instituto Grifols SA   (Spain)

^d UNIVERSITY HOSPITAL BONN   (Germany)

^e CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^f UNIVERSITY OF MILAN   (Italy)

Author keywords

Factor VIII; Immune tolerance induction; Immunogenicity; Inhibitors; Tyrosine 1680; Von Willebrand factor

Indexed keywords

BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 ANTIBODY; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 8 INHIBITOR; BLOOD CLOTTING FACTOR 8 PLUS VON WILLEBRAND FACTOR; CORTISONE; CYCLOPHOSPHAMIDE; DESMOPRESSIN; IMMUNOGLOBULIN; RECOMBINANT BLOOD CLOTTING FACTOR 8; TYROSINE; VON WILLEBRAND FACTOR;

ANIMAL CELL; APHERESIS; BLEEDING; BLOOD CLOTTING; COMPLEX FORMATION; CONFERENCE PAPER; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TREATMENT FAILURE; HEMOPHILIA A; HIGH RISK PATIENT; HUMAN; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; RETROSPECTIVE STUDY; SULFATION; VON WILLEBRAND DISEASE;

BLOOD COAGULATION FACTOR INHIBITORS; FACTOR VIII; HEMOPHILIA A; HEMOSTATICS; HUMANS; IMMUNE TOLERANCE; RECOMBINANT PROTEINS; TYROSINE; VON WILLEBRAND FACTOR;

EID: 84860325637     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2011.02655.x     Document Type: Conference Paper

References (40)

1. von Willebrand EA. Hereditär pseudohemofili. Finska Läkaresällskapets Handlingar 1926; 67: 87-112.
2. Goudemand J, Rothschild C, Demiguel V et al. Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood 2006; 107: 46-51.
3. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003; 9: 418-35.
4. Dasgupta S, Repesse Y, Bayry J et al. VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors. Blood 2007; 109: 610-2.
5. Lenting PJ, van Schooten CJ, Denis CV. Clearance mechanisms of von Willebrand factor and factor VIII. J Thromb Haemost 2007; 5: 1353-60.
6. Lin Y, Yang X, Chevrier MC et al. Relationships between factor VIII:Ag and factor VIII in recombinant and plasma-derived factor VIII concentrates. Haemophilia 2004; 10: 459-69.
7. Koedam JA, Hamer RJ, Beeser-Visser NH, Bouma BN, Sixma JJ. The effect of von Willebrand factor on activation of factor VIII by factor Xa. Eur J Biochem 1990; 189: 229-34.
8. Kreuz W. The role of VWF for the success of immune tolerance induction. Thromb Res 2008; 122(Suppl. 2): S7-12.
9. Michnick DA, Pittman DD, Wise RJ, Kaufman RJ. Identification of individual tyrosine sulfation sites within factor VIII required for optimal activity and efficient thrombin cleavage. J Biol Chem 1994; 269: 20095-102.
10. Leyte A, van Schijndel HB, Niehrs C et al. Sulfation of Tyr1680 of human blood coagulation factor VIII is essential for the interaction of factor VIII with von Willebrand factor. J Biol Chem 1991; 266: 740-6.
11. Higuchi M, Wong C, Kochhan L et al. Characterization of mutations in the factor VIII gene by direct sequencing of amplified genomic DNA. Genomics 1990; 6: 65-71.
12. Higuchi M, Kazazian HH Jr, Kasch L et al. Molecular characterization of severe hemophilia A suggests that about half the mutations are not within the coding regions and splice junctions of the factor VIII gene. Proc Natl Acad Sci USA 1991; 88: 7405-9.
13. Mannucci PM. Treatment of von Willebrand's disease. N Engl J Med 2004; 351: 683-94.
14. Grancha S, Navajas R, Marañon C, Paradela A, Albar JP, Jorquera JI. Incomplete tyrosine 1680 sulphation in recombinant FVIII concentrates. Haemophilia 2011; 17: 709-10.
15. Key NS. Inhibitors in congenital coagulation disorders. Br J Haematol 2004; 127: 379-91.
16. Brackmann HH, Gormsen J. Massive factor-VIII infusion in haemophiliac with factor-VIII inhibitor, high responder. Lancet 1977; 2: 933.
17. Brackmann HH, Oldenburg J, Schwaab R. Immune tolerance for the treatment of factor VIII inhibitors - twenty years''bonn protocol'. Vox Sang 1996; 70(Suppl. 1): 30-5.
18. Dimichele D. Inhibitors: resolving diagnostic and therapeutic dilemmas. Haemophilia 2002; 8: 280-7.
19. Kreuz W, Escuriola-Ettingshausen C, Martinez-Saguer I, Gungor T, Kornhuber B. Epidemiology of inhibitors in haemophilia A. Vox Sang 1996; 70(Suppl. 1): 2-8.
20. Mariani G, Scheibel E, Nogao T et al. Immunetolerance as treatment of alloantibodies to factor VIII in hemophilia. The International Registry of Immunetolerance Protocols. Semin Hematol 1994; 31: 62-4.
21. Smith MP, Spence KJ, Waters EL et al. Immune tolerance therapy for haemophilia A patients with acquired factor VIII alloantibodies: comprehensive analysis of experience at a single institution. Thromb Haemost 1999; 81: 35-8.
22. Freiburghaus C, Berntorp E, Ekman M, Gunnarsson M, Kjellberg B, Nilsson IM. Tolerance induction using the Malmo treatment model 1982-1995. Haemophilia 1999; 5: 32-9.
23. Nilsson IM, Berntorp E, Zettervall O. Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII. N Engl J Med 1988; 318: 947-50.
24. Mauser-Bunschoten EP, Nieuwenhuis HK, Roosendaal G, van den Berg HM. Low-dose immune tolerance induction in hemophilia A patients with inhibitors. Blood 1995; 86: 983-8.
25. Mariani G, Kroner B. Immune tolerance in hemophilia with factor VIII inhibitors: predictors of success. Haematologica 2001; 86: 1186-93.
26. Mariani G, Testa MG, Di Paolantonio T, Molskov BR, Hedner U. Use of recombinant, activated factor VII in the treatment of congenital factor VII deficiencies. Vox Sang 1999; 77: 131-6.
27. Gilles JG, Desqueper B, Lenk H, Vermylen J, Saint-Remy JM. Neutralizing antiidiotypic antibodies to factor VIII inhibitors after desensitization in patients with hemophilia A. J Clin Invest 1996; 97: 1382-8.
28. Sultan Y, Rossi F, Kazatchkine MD. Recovery from anti-VIII:C (antihemophilic factor) autoimmune disease is dependent on generation of antiidiotypes against anti-VIII:C autoantibodies. Proc Natl Acad Sci USA 1987; 84: 828-31.
29. Hausl C, Ahmad RU, Sasgary M et al. High-dose factor VIII inhibits factor VIII-specific memory B cells in hemophilia A with factor VIII inhibitors. Blood 2005; 106: 3415-22.
30. DiMichele DM, Hoots WK, Pipe SW, Rivard GE, Santagostino E. International workshop on immune tolerance induction: consensus recommendations. Haemophilia 2007; 13(Suppl. 1): 1-22.
31. Kallas A, Talpsep T. von Willebrand factor in factor VIII concentrates protects against neutralization by factor VIII antibodies of haemophilia A patients. Haemophilia 2001; 7: 375-80.
32. Berntorp E, Shapiro A, Astermark J et al. Inhibitor treatment in haemophilias A and B: summary statement for the 2006 international consensus conference. Haemophilia 2006; 12(Suppl. 6): 1-7.
33. Suzuki T, Arai M, Amano K, Kagawa K, Fukutake K. Factor VIII inhibitor antibodies with C2 domain specificity are less inhibitory to factor VIII complexed with von Willebrand factor. Thromb Haemost 1996; 76: 749-54.
34. Tagariello G, Zanotto D, Radossi P, Sartori R, Belvini D, Salviato R. In vitro reactivity of factor VIII inhibitors with von Willebrand factor in different commercial factor VIII concentrates. Am J Hematol 2007; 82: 460-2.
35. Astermark J, Voorberg J, Lenk H et al. Impact of inhibitor epitope profile on the neutralizing effect against plasma-derived and recombinant factor VIII concentrates in vitro. Haemophilia 2003; 9: 567-72.
36. Gensana M, Altisent C, Aznar JA et al. Influence of von Willebrand factor on the reactivity of human factor VIII inhibitors with factor VIII. Haemophilia 2001; 7: 369-74.
37. Sadler JE, Budde U, Eikenboom JC et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 2006; 4: 2103-14.
38. Federici AB, Castaman G, Thompson A, Berntorp E. Von Willebrand's disease: clinical management. Haemophilia 2006; 12(Suppl. 3): 152-8.
39. Mannucci PM, Chediak J, Hanna W et al. Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study. Blood 2002; 99: 450-6.
40. Federici AB, Barillari G, Zanon E et al. Efficacy and safety of highly purified, doubly virus-inactivated FVIII/VWF concentrates in inherited von Willebrand's disease: results of an Italian cohort study on 120 patients characterized by bleeding severity score. Haemophilia 2010; 16: 101-10.